<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03815396</url>
  </required_header>
  <id_info>
    <org_study_id>Ph1 INBRX-101</org_study_id>
    <nct_id>NCT03815396</nct_id>
  </id_info>
  <brief_title>Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency</brief_title>
  <acronym>rhAAT-Fc</acronym>
  <official_title>An Open-Label, Multicenter, Phase 1 Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Intravenous Doses of Inhibrx rhAAT-Fc (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency (AATD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inhibrx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inhibrx, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, 2-part, dose-escalating, Phase 1 study of INBRX-101 (rhAAT-Fc). Part 1
      will consist of single ascending dose (SAD) administration of INBRX-101 and Part 2 will
      consist of multiple ascending dose (MAD) administrations of INBRX-101. The planned dosing
      schedule is IV every 3 to 4 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 19, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of adverse events of INBRX-101</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of adverse events of INBRX-101</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>Severity of adverse events will be assessed and assigned by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration time curve (AUC) of INBRX-101</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>Area under the serum concentration time curve (AUC) of INBRX-101 will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of INBRX-101</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>Maximum observed serum concentration (Cmax) of INBRX-101 will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed serum concentration (Ctrough) of INBRX-101</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>Trough observed serum concentration (Cmax) of INBRX-101 will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax) of INBRX-101</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>Time to Cmax (Tmax) of INBRX-101 will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (T1/2) of INBRX-101</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>Half-life of INBRX-101 will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of INBRX-101</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>Frequency and consequences of anti-drug antibodies (ADA) against INBRX-101 will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of INBRX-101 in Bronchoalveolar Lavage Fluid (BALF)</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>The concentration of INBRX-101 in bronchoalveolar lavage fluid (BALF) be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional concentration of INBRX-101 in serum and BALF</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>The functional concentration of INBRX-101 in serum and BALF will be determined.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Alpha-1 Antitrypsin Deficiency</condition>
  <condition>AATD</condition>
  <arm_group>
    <arm_group_label>Part 1 Single Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INBRX-101 will be escalated in subjects with alpha-1 antitrypsin deficiency (AATD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Multiple Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INBRX-101 will be escalated in subjects with alpha-1 antitrypsin deficiency (AATD).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INBRX-101/rhAAT-Fc</intervention_name>
    <description>INBRX-101 is a recombinant human alpha-1 antitrypsin (AAT) Fc fusion protein (rhAAT-Fc).</description>
    <arm_group_label>Part 1 Single Ascending Dose</arm_group_label>
    <arm_group_label>Part 2 Multiple Ascending Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented alpha-1 antitrypsin (AAT) serum concentration &lt;11 Î¼M.

          -  Diagnosis of alpha-1 antitrypsin deficiency (AATD) with any allelic combination with
             exception of the null/null genotype.

          -  For subjects in Part 2 80 and 120 mg/kg cohorts ONLY: post-bronchodilator FEV1 of at
             least 40% of predicted normal value.

          -  For subjects in Part 2 80 and 120 mg/kg cohorts ONLY: subjects eligible for
             bronchoscopy per judgment of investigator.

          -  Nonsmoker for at least 6 months prior to study and must remain nonsmoking for the
             entire study duration.

          -  Adequate hepatic and renal function as defined per protocol.

          -  Willing to undergo current augmentation therapy washout (if applicable) and refrain
             from initiating augmentation therapy, other investigational drug trials for AATD,
             therapy with IV immunoglobulins or monoclonal antibodies during the entire study,
             including follow-up.

        Exclusion Criteria:

          -  Known or suspected allergy to components of INBRX-101 (AAT or human IgG) or pdAAT.

          -  Participation in any investigational drug trial within 30 days prior to this trial, or
             subjects receiving IV immunoglobulins or monoclonal antibodies within 30 days prior to
             this trial.

          -  History of and/or on the waiting list for lung or liver transplant, lobectomy, or lung
             volume reduction surgery.

          -  Acute respiratory tract infection or COPD exacerbation that required antibiotic
             treatment and/or increase in systemic steroid dosage within the 4 weeks prior to
             screening. Subjects are permitted to continue to receive steroids if the investigator
             judges the subject to have a history of stable dosing.

          -  Subjects with ongoing or history of unstable cor pulmonale.

          -  Infection with hepatitis A, B, or C or human immunodeficiency virus (HIV).

          -  Active autoimmune disease or documented history of autoimmune disease that 1) required
             systemic steroids or immune-suppressive medications and 2) tested positive for
             auto-antibodies. Exception: Endocrinopathies managed with hormone replacement therapy
             (HRT).

          -  Current substance and/or alcohol abuse with protocol defined exceptions.

          -  Current narcotics abuse with protocol defined exceptions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus Wagner, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>CMO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cambridge</name>
      <address>
        <city>Cambridge</city>
        <state>East Of England</state>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2GW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 21, 2019</study_first_submitted>
  <study_first_submitted_qc>January 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2019</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alpha-1 antitrypsin deficiency</keyword>
  <keyword>AATD</keyword>
  <keyword>alpha-1 disease</keyword>
  <keyword>AAT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

